Rates of remission and sustained remission by treatment group
| Prednisone taper+rituximab group (N=107) | Avacopan+rituximab group (N=107) | |
| Remission* at week 26, n (%) | 81 (75.7) | 83 (77.6) |
| Estimate of common difference in percentages (95% CI) | 3.0 (−8.3 to 14.2) | |
| Sustained remission† at week 52, n (%) | 60 (56.1) | 76 (71.0) |
| Estimate of common difference in percentages (95% CI) | 16.5 (4.3 to 28.6) | |
| Relapse rate after remission at week 26, n (%) | 11 (13.6) | 6 (7.2) |
| Estimate of common difference in percentages (95% CI) | −7.9 (−17.7 to 2.0) | |
| Relapse rate after remission (BVAS of 0) at any time, n (%)‡ | 21 (20.2) | 9 (8.7) |
| HR (95% CI) | 0.42 (0.19 to 0.91) |
*Remission was defined as a BVAS of 0 and no receipt of glucocorticoids for vasculitis within 4 weeks before the week 26 visit.
†Sustained remission defined as BVAS of 0 at week 26 and week 52 without any use of glucocorticoids for vasculitis during the 4-week periods preceding and including the week 26 and week 52 visits and no relapse between week 26 and week 52.
‡The number of patients who achieved remission at any time was 104 in the prednisone taper group and 104 in the avacopan group.
BVAS, Birmingham Vasculitis Activity Score.